Date: July 22, 2026

Financial Performance Overview

Jubilant Ingrevia Limited reported strong financial results for the quarter ended June 30, 2026 (Q1 FY27).

Key Financial Metrics (All figures in ₹ Crore unless stated):

| Particulars | Q1'FY26 | Q4'FY26 | Q1'FY27 | Q-o-Q | Y-o-Y |

| Total Revenue | 1,038 | 1,179 | 1,300 | 10% | 25% |

| Total EBITDA | 153 | 172 | 209 | 22% | 36% |

| EBITDA Margin (%) | 15% | 15% | 16% | | |

| PAT after Exceptional Items | 75 | 86 | 106 | 22% | 41% |

| PAT Margin (%) | 7% | 7% | 8% | | |

| Basic and Diluted EPS (₹) | 4.7 | 5.5 | 6.7 | 22% | 41% |

Revenue reached a 15-quarter high of ₹1,300 crore, representing 25% YoY growth driven by healthy volume growth and improved realizations.

Segment-Wise Performance Analysis

A. Specialty Chemicals

| Particulars | Q1'FY26 | Q4'FY26 | Q1'FY27 | Q-o-Q | Y-o-Y |

| Segment Revenue | 478 | 516 | 533 | 3% | 11% |

| % Share of Overall Revenue | 46% | 44% | 41% | | |

| EBITDA | 130 | 139 | 139 | 1% | 7% |

| % EBITDA Margin | 27% | 27% | 26% | | |

| % Contribution to EBITDA | 76% | 72% | 60% | | |

Business Updates:

  • Pyridine & Picolines (P&P): Volumes remained steady with pricing improvement on both QoQ and YoY basis
  • Fine Chemicals: YoY volume growth across products with pricing improving; 20+ cosmetics products under development
  • CDMO: Agro segment benefited from roll out of big Innovator CDMO volumes; Pharma saw strong customer traction with 3x+ pipeline expansion; Semiconductor R&D lab with clean room being built at Greater Noida
  • CDMO/Fine Chemicals pipeline shows 100+ molecules with ₹3,500+ crore peak revenue potential, with 25+ confirmed molecules
  • Added 5 new molecules in the last quarter across pharma, semicon and personal care segments

B. Nutrition & Health Solutions

| Particulars | Q1'FY26 | Q4'FY26 | Q1'FY27 | Q-o-Q | Y-o-Y |

| Segment Revenue | 179 | 230 | 243 | 6% | 36% |

| % Share of Overall Revenue | 17% | 20% | 19% | | |

| EBITDA | 25 | 32 | 36 | 12% | 45% |

| % EBITDA Margin | 14% | 14% | 15% | | |

| % Contribution to EBITDA | 14% | 17% | 15% | | |

Business Updates:

  • Human Nutrition: Niacinamide volumes grew with strong pricing across food and cosmetics; Choline Chloride and CBT pricing improved; Premixes strengthened with Tier-1 customers post Remidex integration
  • Animal Nutrition: Vitamin B3 volumes steady with significant pricing improvement; Choline maintained domestic market share with sustained EU traction; Premixes volume growth with favorable product mix
  • Achieved highest EBITDA in the segment over last three years

C. Chemical Intermediates

| Particulars | Q1'FY26 | Q4'FY26 | Q1'FY27 | Q-o-Q | Y-o-Y |

| Segment Revenue | 381 | 433 | 524 | 21% | 38% |

| % Share of Overall Revenue | 37% | 37% | 40% | | |

| EBITDA | 17 | 22 | 57 | 163% | 240% |

| % EBITDA Margin | 4% | 5% | 11% | | |

| % Contribution to EBITDA | 10% | 11% | 24% | | |

Business Updates:

  • Acetic Anhydride: Steady volumes driven by resilient pharma demand; strong double-digit price growth QoQ and YoY
  • Ethyl Acetate: Strong double-digit YoY volume growth; double-digit price improvement QoQ and YoY
  • Growth driven by higher volumes and improved realizations supported by elevated input costs amid Middle East disruptions

Income Statement Details

Q1'FY27 Income Statement (₹ Crore):

  • Total revenue from operations: 1,300
  • Other income: 10
  • Total income: 1,310
  • Expenses:
  • Cost of materials consumed: 718 (60% YoY growth)
  • Purchases of stock-in-trade: 64 (98% YoY growth)
  • Changes in inventories: -153 (-502% YoY)
  • Employee benefits expense: 117 (8% YoY growth)
  • Finance costs: 17 (37% YoY growth)
  • Depreciation and amortization: 51 (25% YoY growth)
  • Other expenses: 355 (Power and fuel: 138, Others: 217)
  • Total expenses: 1,170
  • Profit before share of loss of associate: 141
  • Share of loss of associate: -0.03
  • Profit before tax: 141
  • Tax expense: 43 (Current tax: 43, Deferred tax: -8)
  • Net profit: 106

Management Commentary

Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman:

  • Strong start to FY2027 with healthy financial performance
  • Despite geopolitical uncertainties in Middle East, chemical industry demand remained resilient
  • Pharmaceuticals continued as key growth driver
  • Agrochemicals showed encouraging signs of recovery
  • Nutrition and Personal Care witnessed healthy growth
  • Strong traction with customers in electronics/semicon segment
  • Expect growth to be led by Specialty Chemicals and Nutrition alongside recovery in Acetyls
  • Anticipate sequential improvement in revenue and EBITDA
  • New Multi-Purpose Plant on track for commissioning by end of current calendar year

Mr. Deepak Jain, CEO and MD:

  • Advanced strategic priorities while navigating global challenges
  • Diversified sourcing capabilities and operational agility enabled strong performance
  • Pinnacle journey progress reflected in performance
  • Targeting ₹100 crore of lean savings in FY27
  • Progressing on new MPP plant and Supernova program with GenAI use cases
  • Cleared over 20 customer quality and EHS audits
  • Zero safety incidents across manufacturing facilities
  • Completed integration of Remidex Pharma
  • Actively evaluating new growth opportunities in Electronics & Semiconductors, Cosmetics, and Nutrition
  • Hosted successful Investor & Analyst Day at Bharuch facility

Operational and Strategic Updates

Pinnacle Vision Progress:

  • KAM Program: High engagement with top 40 customers; 100+ opportunities in funnel
  • Customer roadshows in EU, US, Japan with 100+ meetings each year
  • Launched new verticals: Semicon, Human Nutrition, Cosmetics/Personal Care, Electronics
  • Expansion in focused markets: US scale up; Japan/SEA focus
  • USFDA plant with zero observations
  • WEF Lighthouse award (Bharuch)
  • Shift to green power (35% share)
  • British Safety awards for key sites
  • Multiple new plants constructed (₹2,000 crore deployed)
  • Lean savings of 100+ Crores/year
  • R&D team expanded to 150+ scientists
  • 50+ products in pipeline
  • Digital/AI initiatives across organization
  • Great Place To Work certified

ESG and Recognition:

  • Certified as Great Place to Work
  • Ranked among Top 50 Manufacturing Companies for FY2027
  • Gajraula facility earned Distinction at British Safety Council International Safety Awards
  • Bharuch and Nira sites also recognized at British Safety Council awards
  • Responsible Care certified company
  • Ranked highly in global ESG indices (Ecovadis and Dow Jones Sustainability Index)
  • Recognized by World Economic Forum and entered Global Lighthouse Network for 4IR technologies deployment

Future Outlook

  • Expect sequential improvement in revenue and EBITDA over coming quarters
  • Growth led by Specialty Chemicals and Nutrition, alongside recovery in Acetyls
  • New Multi-Purpose Plant commissioning by end of current calendar year
  • Strong CDMO and Fine Chemicals growth roadmap
  • Continued progress on Pinnacle strategy

Company Background

Jubilant Ingrevia Limited is a leading player in Specialty Chemicals & CDMO globally, serving Pharmaceutical, Nutrition, Agrochemical, Consumer, Semiconductor and Industrial customers. Portfolio of 130+ products. Over 45 years of legacy in chemicals industry. Among top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3. 50+ plants across 5 manufacturing facilities in India. Workforce of over 2,300 employees. Three R&D centres with 150 scientists.